Shaw P H, Olszewski M, Kletzel M
Department of Pediatrics, University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh, Pittsburgh, PA 15213, USA.
J Hematother Stem Cell Res. 2001 Jun;10(3):391-403. doi: 10.1089/152581601750288993.
Umbilical cord blood (UCB) is now commonly used as a source of stem cells for hematopoietic reconstitution following myeloablative therapy in patients with a variety of diseases. Although UCB is a rich source of stem cells, platelet engraftment occurs at a median of 71 days which is significantly prolonged compared to allogeneic bone marrow. The number of megakaryocyte (MK) precursors in stem cell harvests appears to correlate inversely with the time to platelet engraftment. In an effort to increase the number of platelet precursors, we cultured CD34-selected cord blood mononuclear cells (MNC) in serum-free collagen medium with numerous cytokine combinations. The cells were cultured with four cytokines: interleukin-3 (IL-3), thrombopoietin (TPO), stem cell factor (SCF), and Flt-3); five cytokines, IL-3, TPO, SCF, Flt-3 plus granulocyte-macrophage colony-stimulating factor (GM-CSF), or erythropoietin (Epo); or all six cytokines in combination. After 16 days, significant expansion of MK precursors (CD41(+)) and stem cells (CD34(+) and AC133(+) cells) were seen in cells cultured in IL-3, TPO, SCF, and Flt-3 with or without GM-CSF compared to the combinations that contained Epo (p < 0.05). Similar studies were performed using liquid culture medium, and after 14 days the number of MNCs, CD34(+), AC133(+), CD41(+), and CD61(+) cells were higher in the UCB cells cultured in IL-3, TPO, SCF, and Flt-3 compared to those cultured with those four cytokines plus GM-CSF. These results demonstrate that UCB stem cells can be effectively expanded ex vivo and enriched with platelet precursors using TPO, SCF, Flt-3, and IL-3, whereas the addition of Epo and GM-CSF is unnecessary.
脐带血(UCB)目前常用于多种疾病患者接受清髓性治疗后造血重建的干细胞来源。尽管脐带血是丰富的干细胞来源,但血小板植入的中位时间为71天,与异基因骨髓相比明显延长。干细胞收获物中巨核细胞(MK)前体细胞的数量似乎与血小板植入时间呈负相关。为了增加血小板前体细胞的数量,我们在无血清胶原培养基中用多种细胞因子组合培养CD34选择的脐带血单个核细胞(MNC)。细胞分别与四种细胞因子(白细胞介素-3(IL-3)、血小板生成素(TPO)、干细胞因子(SCF)和Flt-3)、五种细胞因子(IL-3、TPO、SCF、Flt-3加粒细胞-巨噬细胞集落刺激因子(GM-CSF)或促红细胞生成素(Epo))或六种细胞因子联合培养。16天后,与含有Epo的组合相比,在添加或不添加GM-CSF的IL-3、TPO、SCF和Flt-3培养的细胞中,观察到MK前体细胞(CD41(+))和干细胞(CD34(+)和AC133(+)细胞)显著扩增(p<0.05)。使用液体培养基进行了类似研究,14天后,与用这四种细胞因子加GM-CSF培养的脐带血细胞相比,在IL-3、TPO、SCF和Flt-3培养的脐带血细胞中,单个核细胞、CD34(+)、AC133(+)﹑CD41(+)和CD61(+)细胞的数量更高。这些结果表明,使用TPO、SCF、Flt-3和IL-3可以有效地在体外扩增脐带血干细胞并富集血小板前体细胞,而添加Epo和GM-CSF是不必要的。